Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 ...
Lifecore Biomedical’s Strategic Asset Sale Supports Hold Rating Amid Leverage Concerns
Barrington analyst Michael Petusky has maintained their neutral stance on LFCR stock, giving a Hold rating on January 3.Stay Ahead of the ...
Contract Pharma2d
Lifecore Biomedical Sells Excess Capital Equipment for $17M
Lifecore Biomedical Inc., a fully integrated contract development and manufacturing organization (CDMO), has entered into a ...
Stocks to Watch: Lifecore Biomedical, Resources Connection
Lifecore Biomedical beat estimates in its fiscal second quarter. The company, which develops and manufactures pharmaceutical products, reported a per-share loss of 25 cents for the quarter ended Nov.